Table 1 Alternative splicing signatures associated with overall survival in patients with BRCA
From: Characterization of alternative splicing events and prognostic signatures in breast cancer
AS type | Formula | HR (95% CI) | AUC |
|---|---|---|---|
AA | (BRPF3|75960|AA×-6.16)+(TMEM25|19023|AA×-2.96)+(TMEM25|19017|AA×-2.3)+(EIF4G3|957|AA×2.01)+(SLC38A6|27787|AA×-1.91)+(PNPLA8|81412|AA×-2.33)+(SAFB|46852|AA×-3.57)+(PJA1|89360|AA×1.47)+(CAMTA2|38638|AA×-1.34)+(DBF4|80345|AA×10.15)+(SMG7|9181|AA×3.66)+(PSMD13|13632|AA×-0.61)+(ELF1|25724|AA×-22.6)+(ZNF268|25354|AA×10.09)+(SEC24D|70448|AA×3.56)+(PKMYT1|33330|AA×-1.27)+(ATXN3|28923|AA×-15.55)+(GGT5|61393|AA×-2.62) | 6.369 (3.753-10.807) | 0.697 |
AD | (POMT1|87937|AD×-1.65)+(ENOPH1|69708|AD×-3.16)+(FCF1|28425|AD×-3.4)+(DCAF11|26842|AD×-5.4)+(OBSL1|57731|AD×-4.41)+(ARSA|62901|AD×2.52)+(HNRNPUL1|50039|AD×-1.14)+(FRMD6|27515|AD×-1.89)+(RNF41|22407|AD×3.64)+(TVP23C|39359|AD×-4.64)+(FBXL12|47433|AD×2.69)+(C7orf49|81873|AD×-2.3)+(SEC31A|100880|AD×6.21)+(NKG7|51322|AD×-18.81)+(PTBP3|87243|AD×2.33)+(BCL2L11|54966|AD×-2.19)+(PDGFC|70954|AD×-8.91) | 5.365 (3.172-9.074) | 0.751 |
AP | (ANK3|11845|AP×1.14)+(HSPBP1|52052|AP×-3.16)+(RPS6KA1|1282|AP×2.6)+(NR1H3|15695|AP×-1.42)+(SH3BP2|68591|AP×1.82)+(KLF11|52654|AP×3.89)+(APOC2|50372|AP×-4.67)+(MEF2A|32713|AP×6.02)+(RAD21|84981|AP×-5.01)+(MOK|29361|AP×-3.24)+(TOP1MT|85413|AP×-9.73)+(SPAG9|42493|AP×1.79) | 3.112 (2.000-4.844) | 0.703 |
AT | (USH2A|9805|AT×-8.17)+(CYP4B1|2832|AT×-3.23)+(EYS|76614|AT×-4.42)+(DAPL1|55687|AT×-0.77)+(CDK15|56923|AT×-3.48)+(TNFRSF13B|39449|AT×-1.13)+(ATRNL1|13220|AT×1.57)+(CLEC3A|37670|AT×0.56)+(EFCAB13|42070|AT×-1.38)+(CHRNA1|56036|AT×-5.08)+(FAM184A|77360|AT×3.36)+(C3orf55|67409|AT×1.55) | 3.877 (2.423-6.203) | 0.72 |
ES | (PARPBP|24031|ES×-0.97)+(NCOR1|39424|ES×-3.52)+(UBE2V1|59762|ES×-4.81)+(HNRNPM|94942|ES×-5.83)+(ITGB5|100223|ES×-10.88)+(CNST|10497|ES×-4.78)+(SCLY|58203|ES×-4.27)+(SUV420H1|17300|ES×-7.95)+(ARHGAP12|11155|ES×-2.64)+(HARS2|73762|ES×-11.75)+(BTN3A2|75634|ES×-2.49)+(FDFT1|82653|ES×-1.36)+(RCSD1|8870|ES×-3.22)+(TDG|24084|ES×-3.41)+(FCGR2B|8681|ES×-2.17)+(BCL2L11|54967|ES×-1.75)+(ENOSF1|44469|ES×-4.23) | 5.327 (3.240-8.756) | 0.769 |
ME | (COPS5|115459|ME×1.67)+(GOLT1B|92984|ME×1.41)+(GRB10|79717|ME×-0.81)+(CPSF7|99751|ME×-1.12)+(SORBS2|71377|ME×2.69)+(SRGAP1|93242|ME×2.17)+(PTK2|98071|ME×2.21) | 2.853 (1.833-4.440) | 0.667 |
RI | (PRX|49900|RI×1.3)+(COPZ1|22159|RI×-2.86)+(PHTF1|4284|RI×1.73)+(SV2B|32540|RI×-4.98)+(CHTF8|37263|RI×-9.28)+(AK9|77206|RI×-3.77)+(GLI4|85407|RI×-1.26)+(MTF2|3771|RI×-5.62)+(PCSK7|18902|RI×-2.86)+(PDGFC|70956|RI×-9.44)+(HYAL1|64998|RI×-2.72)+(DERL3|61334|RI×1.31)+(CD59|14911|RI×-9.36)+(KIAA0895L|36957|RI×6.12) | 4.667 (2.856-7.626) | 0.767 |
ALL | (PARPBP|24031|ES×-0.91)+(NCOR1|39424|ES×-5.48)+(COPZ1|22159|RI×-2.44)+(ANK3|11845|AP×0.62)+(ITGB5|100223|ES×-22.45)+(PHTF1|4284|RI×2.17)+(HSPBP1|52052|AP×-3.02)+(TCF12|30783|AP×1.47)+(RPS6KA1|1282|AP×2.47)+(CNST|10497|ES×-3.92)+(TMEM25|19023|AA×-2.99)+(TMEM25|19017|AA×-1.08)+(BTN3A2|75630|ES×-2.65) | 5.175 (3.093-8.659) | 0.801 |